Platinum Compounds - Revision history

Lazy at 08:22, 18 January 2025

2025-01-18T08:22:18Z

← Older revision		Revision as of 01:22, 18 January 2025
Line 21:		Line 21:
	high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied,		high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied,
	median survival was 25 months.		median survival was 25 months.
	}}		\|overview=Platinum Compounds, particularly cisplatin, are FDA-approved chemotherapy agents used in the treatment of glioblastoma, showing improved progression-free survival when combined with Temodar and etoposide, despite a high toxicity profile characterized by nephrotoxicity, ototoxicity, and neurotoxicity. Clinical trials indicate a median survival of 25 months for patients receiving this combination therapy, though significant risks must be discussed with healthcare providers.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:34:08Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:34, 12 November 2024
Line 8:		Line 8:
	\|usefulness_rating=3		\|usefulness_rating=3
	\|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.		\|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
	\|~~category~~=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma.		\|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma.

Lazy at 04:18, 28 March 2024

2024-03-28T04:18:55Z

← Older revision		Revision as of 21:18, 27 March 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Platinum Compounds ~~(Cisplatin)~~		\|drug_name=Platinum Compounds
	\|FDA_approval=Yes		\|FDA_approval=Yes
	\|used_for=Glioblastoma		\|used_for=Glioblastoma
Line 11:		Line 11:
	\|toxicity_level=4		\|toxicity_level=4
	\|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma.		\|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma.
			\|book_text=An improvement in results relative to those obtained with Temodar alone has also been
			reported when Temodar has been combined with cisplatin. In a pair of clinical studies
			performed in Italy (61, 62) with patients with recurrent tumors, the PFS-6 was 34% and
			35%. A treatment protocol with newly diagnosed patients that also seems to have
			produced better results than Temodar as a single agent combined Temodar with both
			cisplatin and etoposide (VP-16), given through the carotid artery (63). Cisplatin and
			etoposide were given after surgery and continued for three cycles spaced every 3 weeks
			apart, followed by the standard protocol of radiation plus low-dose Temodar, then
			high-dose Temodar on the schedule of days 1-5 of every month. For 15 patients studied,
			median survival was 25 months.
	}}		}}

Lazy at 16:55, 27 March 2024

2024-03-27T16:55:50Z

← Older revision		Revision as of 09:55, 27 March 2024
Line 9:		Line 9:
	\|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.		\|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
			\|toxicity_level=4
			\|toxicity_explanation=The treatment with Platinum Compounds (Cisplatin) is considered relatively high in toxicity due to potential side effects like kidney damage (Nephrotoxicity), hearing loss (ototoxicity), and nervous system damage (neurotoxicity). It's important for patients to discuss these risks with their healthcare provider before starting therapy. A toxicity level of 4 out of 5 means this treatment carries significant risks, but it may be necessary for managing glioblastoma.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Platinum Compounds (Cisplatin) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Various, including Phase II |common_side_effects=Nephrotoxicity, ototoxicity, and neurotoxicity |OS_with=Not specified |usefulness_rating=3 |notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months. |category=Other Chemotherapy and C..."

2024-03-24T13:10:55Z

Created page with "{{TreatmentInfo |drug_name=Platinum Compounds (Cisplatin) |FDA_approval=Yes |used_for=Glioblastoma |clinical_trial_phase=Various, including Phase II |common_side_effects=Nephrotoxicity, ototoxicity, and neurotoxicity |OS_with=Not specified |usefulness_rating=3 |notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months. |category=Other Chemotherapy and C..."

New page

{{TreatmentInfo
|drug_name=Platinum Compounds (Cisplatin)
|FDA_approval=Yes
|used_for=Glioblastoma
|clinical_trial_phase=Various, including Phase II
|common_side_effects=Nephrotoxicity, ototoxicity, and neurotoxicity
|OS_with=Not specified
|usefulness_rating=3
|notes=Combining Temodar with cisplatin has shown improved PFS-6 in recurrent tumors. A protocol combining Temodar, cisplatin, and etoposide reported median survival of 25 months.
|category=Other Chemotherapy and Cancer Drugs
}}